BioMedNewsBreaks

ThursdayJul 25, 2024 1:29 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CMO to Present Poster at Upcoming SNO/ASCO CNS Cancer Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in next month’s 2024 SNO/ASCO CNS Cancer Conference. The event will be held Aug. 8–10 in Denver. According to the announcement, CNS Pharmaceuticals has an abstract, titled “Use of a Brain-Penetrating Anthracycline in Anthracycline-Sensitive Brain Metastases: The Promise of Berubicin,” that has been selected for poster presentation at the conference. CNS Pharmaceuticals chief medical officer Sandra Silberman, MD, PhD, will be presenting. The presentation is slated from 7:15–9 p.m. MT on Aug.…

Continue Reading

WednesdayJul 24, 2024 1:58 pm

BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Holds Annual General and Special Meeting of Shareholders, Reports on Voting Results

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is reporting on the results of its annual general and special meeting of shareholders; the in-person meeting was held on July 22, 2024, in Toronto, Ontario. According to the report, shareholders were represented in person or by proxy at the meeting. Shareholders elected seven directors for the company, with the directors serving until the next annual meeting or until a successor is elected or appointed; the elected directors include Anthony Durkacz, Zeeshan Saeed, Dr. Lakshmi P. Kotra, Adnan…

Continue Reading

WednesdayJul 24, 2024 11:23 am

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives US Patent for Methods of Treating Acute Traumatic Brain Injury with Its Lead Drug Candidate

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent covers methods of treating acute traumatic brain injuries (“TBI”) and preventing nerve cell death with its lead drug candidate, buntanetap. Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This improves synaptic transmission, axonal transport, and reduces neuroinflammation. “We are thrilled to achieve this significant milestone for buntanetap,” said Maria Maccecchini, Ph.D., Founder,…

Continue Reading

TuesdayJul 23, 2024 11:10 am

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives PEI Feedback Regarding Development, Preclinical Trial of Anti-IL-17 NanoAb

Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, has received the minutes of meeting from a recent Scientific Advice (“SA”) with the Paul Erlich Institute, Federal Institute for Vaccines and Biomedicines (“PEI”). According to the announcement, this is the European equivalent to a pre-IND meeting with the U.S. Food and Drug Administration in the United States as well as acceptable guidance for Investigational Medicinal Product Dossier (“IMPD”) filing with the European Medicines Agency (“EMA”). The company noted…

Continue Reading

MondayJul 22, 2024 12:06 pm

BioMedNewsBreaks — Onassis Holdings Corp. (ONSS) Enters Agreement with Dalmore Group for Reg A+ Offering

Onassis Holdings (OTC: ONSS), a wellness- and biotech-focused holding company, has launched a round of Regulation A+ financing. The company has entered an agreement with Dalmore Group for the fundraising initiative. According to the announcement, Reg A+ funding offers a streamlined method for companies to raise up to $75 million a year from the public. “In aligning with Dalmore Group, Onassis looks to leverage the investment bank's prowess in capital raising through Regulations A+, CF and D,” stated the announcement. “Since 2021, Dalmore has on-boarded over 270 Reg A+ issuers, establishing itself as a leader in Reg A+ financing services. With over…

Continue Reading

FridayJul 19, 2024 10:27 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Execs to Participate in July 25 Investor Webinar

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is inviting investors to a live webinar. Scheduled for July 25, 2024, at 4:15 p.m. ET, this exclusive event will be hosted by RedChip Companies. During the webinar, Nutriband Chairman and President Serguei Melnik and CEO Gareth Sheridan will share insights into the company’s current operations and upcoming milestones. To register for the free webinar, visit https://ibn.fm/ZZkgn To view the full press release, visit https://ibn.fm/xnDGN About Nutriband Inc. Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development…

Continue Reading

WednesdayJul 17, 2024 1:06 pm

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at the 73rd Emerging Growth Conference

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company is presenting at the 73rd Emerging Growth Conference, scheduled for July 17-18, 2024. Clene’s presentation is slated to begin at 4:45 p.m. EDT on July 18, with Rob Etherington, Clene’s President and CEO, and Morgan Brown, Clene’s CFO, giving the presentation. To view the full press release, visit https://ibn.fm/kt4FO About Clene Inc. Clene (along with…

Continue Reading

WednesdayJul 17, 2024 10:25 am

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Enters Strategic Partnership to Support Rollout of Telemedicine Services across the US

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, is announcing a strategic partnership with HC Smart, Inc., a national telemedicine provider. The partnership, set to go live within the next four weeks, is expected to extend HealthLynked’s telemedicine services across the U.S. as well as significantly enhance the company’s offerings and accessibility. The announcement stated that the collaboration will integrate HC Smart’s advanced telemedicine capabilities into HealthLynked’s existing platform, providing nationwide coverage to all HealthLynked members. This initiative will offer HealthLynked Network members access to high-quality healthcare from the comfort of their homes by enabling reduced-cost telemedicine consultations as part…

Continue Reading

TuesdayJul 16, 2024 3:38 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names New Medical Advisory Board Member

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, has appointed a new member to its medical advisory board. According to the announcement, Mark Gilbert, MD, will be joining the board, bringing board membership to eight. A scientist emeritus at the National Institutes of Health (“NIH”), Gilbert served as chief of the neurooncology branch at NIH for a decade. During that time, Gilbert facilitated a team of laboratory and clinical investigators involved in groundbreaking research that advanced science in the brain tumor field. In addition to his experience at NIH, Gilbert practiced under world-renowned…

Continue Reading

TuesdayJul 16, 2024 3:00 pm

BioMedNewsBreaks — Bluejay Diagnostics Inc. (NASDAQ: BJDX) Closes $8.75M Underwritten Public Offering

Bluejay (NASDAQ: BJDX), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, recently announced the closing of a firm commitment underwritten public offering. Expected gross proceeds to the company were approximately $8.75 million. The base offering consisted of 5,368,098 common units or prefunded units, each unit consisting of one share of the company’s common stock or one pre-funded warrant to purchase one share of common Stock, two Class C warrants each to purchase one share of common stock and one Class D warrant to purchase such number of shares of…

Continue Reading